Precipio announces new customer to bring total Q4 HemeScreen revenues to $1.2M

Precipio announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. As of today, Precipio forecasts product revenue in Q4 which is within $300,000 of quarterly cash flow breakeven. Adding these new customers brings the company to approximately $1.2M in product revenue, or 80% of that goal. “We are seeing repeated confirmation that our HemeScreen product line stands head & shoulders above competition and alternative diagnostic products when it comes to robustness, ease of use, and economics, and this has translated into a very high close rate,” said Ilan Danieli, CEO. “Although the sales cycle is often lengthy, the good news is that the adoption rate is high. This tells us that it is not a matter of “if”, but rather a matter of “when” the laboratory becomes our customer. I am encouraged by these results which move us closer to meeting our short-term cash flow breakeven goals; as well as an indication of our ability to capture substantial market share.”